ATE371724T1 - Behandlung neurodegenerativer krankheiten - Google Patents

Behandlung neurodegenerativer krankheiten

Info

Publication number
ATE371724T1
ATE371724T1 AT04764730T AT04764730T ATE371724T1 AT E371724 T1 ATE371724 T1 AT E371724T1 AT 04764730 T AT04764730 T AT 04764730T AT 04764730 T AT04764730 T AT 04764730T AT E371724 T1 ATE371724 T1 AT E371724T1
Authority
AT
Austria
Prior art keywords
treatment
neurodegenerative diseases
fads2
medicament
inhibitors
Prior art date
Application number
AT04764730T
Other languages
English (en)
Inventor
Carsten Hopf
Original Assignee
Cellzome Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/EP2003/013980 external-priority patent/WO2005023858A1/en
Application filed by Cellzome Ag filed Critical Cellzome Ag
Application granted granted Critical
Publication of ATE371724T1 publication Critical patent/ATE371724T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4711—Alzheimer's disease; Amyloid plaque core protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0083—Miscellaneous (1.14.99)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Neurology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
AT04764730T 2003-09-05 2004-09-02 Behandlung neurodegenerativer krankheiten ATE371724T1 (de)

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
EP03019642 2003-09-05
PCT/EP2003/013980 WO2005023858A1 (en) 2003-09-05 2003-12-10 Protein complexes associated with app-processing
EP04001895 2004-01-29
EP04001894 2004-01-29
EP04007447 2004-03-26
EP2004004891 2004-05-07
EP2004004889 2004-05-07
EP04018874 2004-08-09
EP04764730A EP1670903B1 (de) 2003-09-05 2004-09-02 Behandlung neurodegenerativer krankheiten

Publications (1)

Publication Number Publication Date
ATE371724T1 true ATE371724T1 (de) 2007-09-15

Family

ID=37035440

Family Applications (1)

Application Number Title Priority Date Filing Date
AT04764730T ATE371724T1 (de) 2003-09-05 2004-09-02 Behandlung neurodegenerativer krankheiten

Country Status (8)

Country Link
US (1) US20060216292A1 (de)
EP (1) EP1670903B1 (de)
AT (1) ATE371724T1 (de)
CA (1) CA2537844A1 (de)
DE (1) DE602004008658T2 (de)
DK (1) DK1670903T3 (de)
ES (1) ES2291917T3 (de)
WO (1) WO2005023833A2 (de)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7094572B2 (en) 2003-03-14 2006-08-22 Bristol-Myers Squibb Polynucleotide encoding a novel human G-protein coupled receptor variant of HM74, HGPRBMY74
US20100098682A1 (en) * 2005-06-14 2010-04-22 D Adamio Luciano Effect of Bri Proteins on Ass Production
EP2043428A4 (de) * 2006-07-13 2011-11-02 Burnham Inst Medical Research Modulatoren von rnf5 und ihre verwendungen
US20100169988A1 (en) * 2006-12-06 2010-07-01 Bernhard Kohli Means and methods for isolating and determining novel targets for the treatment of neurodegenerative, neurological or neuropsychiatric disorders and compositions comprising the same
PL3225251T3 (pl) 2006-12-21 2020-06-29 H. Lundbeck A/S Modulacja aktywności proneurotrofin
EP2111252A4 (de) * 2007-01-31 2010-12-01 Adam Heller Elektrochemische schmerzbehandlung
CN102300582A (zh) 2009-01-30 2011-12-28 阿尔法贝塔公司 用于治疗阿尔茨海默病的化合物和方法
US9522170B2 (en) * 2011-04-05 2016-12-20 Alphabeta Ab Methods of screening compounds for the fibril formation of Aβ peptides based on a decreased trimer/monomer ratio of a chaperone protein
WO2012140148A2 (en) * 2011-04-12 2012-10-18 Universität Zürich Prorektorat Mnw Junction plakoglobin for diagnosis of cardiovascular diseases
KR101511737B1 (ko) * 2012-12-31 2015-04-20 대한민국 Sumo1 및 bace1의 결합 억제제를 유효성분으로 함유하는 퇴행성 뇌질환 예방 및 치료용 약학적 조성물
CN109715194B (zh) 2016-08-03 2024-06-11 南佛罗里达大学 用于治疗神经障碍的颤蛋白组合物
EP3529245A4 (de) 2016-10-24 2020-12-23 Yumanity Therapeutics, Inc. Verbindungen und verwendungen davon
KR101873249B1 (ko) 2016-11-08 2018-07-05 대한민국 혈액기반 유전자 발현패턴을 이용한 치매 진단 방법
MA47212A (fr) 2017-01-06 2019-11-13 Yumanity Therapeutics Inc Méthodes de traitement de troubles neurologiques
WO2019084157A1 (en) 2017-10-24 2019-05-02 Yumanity Therapeutics, Inc. COMPOUNDS AND USES THEREOF
ES3043183T3 (en) 2018-03-23 2025-11-25 Janssen Pharmaceutica Nv Compounds and uses thereof
MA54829A (fr) 2019-01-24 2021-12-01 Yumanity Therapeutics Inc Composés et leurs utilisations
CN110144360B (zh) * 2019-06-06 2021-03-16 华中农业大学 一种二化螟SDR基因及其编码的蛋白质和应用、dsRNA及其扩增的引物对和应用
EA202192047A1 (ru) 2019-11-13 2021-12-08 Юманити Терапьютикс, Инк. Соединения и их применение
CN112641948A (zh) * 2020-12-25 2021-04-13 西北农林科技大学 靶基因SLC4A8在制备调控乳腺上皮细胞分泌β酪蛋白的药物的应用
CN116139277B (zh) * 2021-11-23 2025-06-24 中国科学院大连化学物理研究所 肝癌药物的辅助治疗药物及应用和治疗肝癌药物混合物

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) * 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) * 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4683195A (en) * 1986-01-30 1987-07-28 Cetus Corporation Process for amplifying, detecting, and/or-cloning nucleic acid sequences
US4683202A (en) * 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US4889818A (en) * 1986-08-22 1989-12-26 Cetus Corporation Purified thermostable enzyme
HU202728B (en) * 1988-01-14 1991-04-29 Eszakmagyar Vegyimuevek Synergetic fungicide and acaricide compositions containing two or three active components
US5223409A (en) * 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5530101A (en) * 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5096815A (en) * 1989-01-06 1992-03-17 Protein Engineering Corporation Generation and selection of novel dna-binding proteins and polypeptides
US5198346A (en) * 1989-01-06 1993-03-30 Protein Engineering Corp. Generation and selection of novel DNA-binding proteins and polypeptides
US5498538A (en) * 1990-02-15 1996-03-12 The University Of North Carolina At Chapel Hill Totally synthetic affinity reagents
US5661016A (en) * 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) * 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5633425A (en) * 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) * 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ES2246502T3 (es) * 1990-08-29 2006-02-16 Genpharm International, Inc. Animales no humanos transgenicos capaces de producir anticuerpos heterologos.
US5582981A (en) * 1991-08-14 1996-12-10 Gilead Sciences, Inc. Method for identifying an oligonucleotide aptamer specific for a target
EP1035207A1 (de) * 1999-03-09 2000-09-13 MultiGene Biotech GmbH cDNA Moleküle der Mitglieder der Genfamilie, die für menschliche Fettsäuredesaturasen kodieren, und deren Verwendung in Diagnostik und Therapie
JP2004507202A (ja) * 1999-03-31 2004-03-11 キュラジェン　コーポレイション ポリペプチドをコードするオープンリーディングフレームを含む核酸；「ｏｒｆｘ」
DE10000161A1 (de) * 2000-01-06 2001-07-19 Boehringer Ingelheim Pharma Verfahren zur Identifikation eines Proteaseinhibitors
EP1257633A1 (de) * 2000-02-25 2002-11-20 Vlaams Interuniversitair Instituut voor Biotechnologie vzw. Presenilin defizient
CA2301158A1 (en) * 2000-03-24 2001-09-24 Stephen J. Allen Screening methods for compounds useful for modulating lipid metabolism in disease

Also Published As

Publication number Publication date
WO2005023833A3 (en) 2005-06-23
CA2537844A1 (en) 2005-03-17
EP1670903B1 (de) 2007-08-29
DE602004008658D1 (de) 2007-10-11
EP1670903A2 (de) 2006-06-21
ES2291917T3 (es) 2008-03-01
DK1670903T3 (da) 2008-01-02
WO2005023833A2 (en) 2005-03-17
DE602004008658T2 (de) 2008-06-12
US20060216292A1 (en) 2006-09-28

Similar Documents

Publication Publication Date Title
DE602004008658D1 (de) Behandlung neurodegenerativer krankheiten
TW200420550A (en) Thiazole compounds for the treatment of neurodegenerative disorders
GT200500060A (es) Compuestos de imidazol para el tratamiento de trastornos neurodegenerativos
CY1108514T1 (el) Παραγωγα 1-φαινυλαλκανεκαρβοξυλικου οξεος για τη θεραπεια νευρογενων ασθενειων
BR0315158A (pt) Compostos de pirazol para o tratamento de distúrbios neurodegenarativos
DE602004028150D1 (de) Aminopyrazolderivate als gsk-3-inhibitoren
EA200600971A1 (ru) Применение замещённых 2 - аминотетралинов для профилактического лечения болезни паркинсона
DE50311898D1 (de) Fredericamycin-derivate als arzneimittel zur tumorbehandlung
ATE409480T1 (de) Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren
ATE392471T1 (de) Behandlung neurodegenerativer krankheiten durch verwendung von scd4-inhibitoren
BR0316723A (pt) Derivados de anilinopirazol úteis para o tratamento de diabetes
EA201070367A1 (ru) Производное 6-пиримидинилпиримид-4-она
TW200716152A (en) Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture
BRPI0509477A (pt) compostos de sulfonamida para o tratamento de distúrbios neurodegenerativos
EA200501865A1 (ru) Аналоги тиовольфраматов и их применение
ATE524171T1 (de) Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion bei der behandlung der parkinson-krankheit
ATE399758T1 (de) Derivate von 1-phenylalkancarbonsäuren zur behandlung von neurodegenerativen krankheiten
EA200600115A1 (ru) Производные 2-аминобензойной кислоты
BRPI0509464A (pt) compostos tiazol sulfonamida para o tratamento de distúrbios neurodegenerativos
BRPI0509881A (pt) combinação terapêutica para tratamento da doença de alzheimer
EP1912963A4 (de) Cyclische ketale als beta-sekretase-inhibitoren zur behandlung von alzheimer-krankheit

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties